GT1 - Megathread, page-1372

First 1372 Last

Share
Profile

Follow
Helvetet

1,894 Posts.

251

25/03/24

11:58

Post #: 73041753
Share

Originally posted by dc1234: ↑

So another weak play here?.
.
Yes after recent 21.5, a play back at 14 level. So playing with weakness. For the whole week, it played with weakness, but in a narrow trading range between 14 and 16.5, but mostly around 14.5/15. So not great at this stage.
.
From a weekly perspective, loss from 16 to 14.
.
Personally, I had bought some at 16.5, I let go this week at 16 at a slight loss, but was not a big play for me. I was hoping for a rebound, but when i didn't see that coming in Li macro, I let go a few Li stocks. I have always written that price action is most important for me, but earlier in the week, I didn't get a good feel around Li play, and I let go some including GT1. I am waiting now to see where I pick up. I know I will. I am reasonably confident that I may write I am holding next week, because I am looking for it, so watching carefully now. Overall though, not a great look, I wouldn't have been unhappy about 14, but to suddenly drop from 21.5, some may think it has gone ahead when it reached 11. So a tough play for holders coming up. I know people don't like when I sell. But I am very clear, when I don't like a price action, I exit. Fundamental is great, but not better than price action. Hope people understand why I got out rather than trash me for selling.

For those interested how stock is tracking against other Lithium stocks or who hold multiple Lithium stocks, I do a Weekly Report across 96 ASX Li stocks. It has got Weekly/Yearly data how stocks are tracking. I also have commentary across general markets and sector. Those just holding specific stocks, it may not be relevant, so please ignore.
Here is the report for this week.
.
.
https://hotcopper.com.au/threads/sya-weekly-report.6951924/page-3#post-73029125
.

Expand

Yeah GT1 showing weakness all last week, it could potentially go test the lows again considering how quiet things are..

LIT etf doesn’t look terrible, this week might change that.

GT1 Price at posting: 13.5¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 91 more messages in this thread...

First 1372 Last

Add GT1 (ASX) to my watchlist

(20min delay)
Last 9.2¢		Change 0.002(2.22%)		Mkt cap ! $35.76M

Open	High	Low	Value	Volume
9.0¢	9.4¢	9.0¢	$23.40K	255.4K

Buyers (Bids)

No.	Vol.	Price($)
1	24963	9.1¢

Sellers (Offers)

Price($)	Vol.	No.
9.4¢	106643	2

View Market Depth

No.	Vol.	Price($)
1	24963	0.091
1	60740	0.090
1	56011	0.089
1	11300	0.088
1	28895	0.087

Price($)	Vol.	No.
0.094	106643	2
0.099	100000	1
0.100	196021	1
0.105	179332	2
0.110	95000	1

Last trade - 15.33pm 07/10/2024 (20 minute delay)

GT1 (ASX) Chart

GT1 - Megathread, page-1372

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

GT1 - Megathread, page-1372

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News